min/1.73 m 2 ) were excluded.Urinary podocalyxin levels were measured using a commercially available ELISA, and their associations with clinical factors and neonatal status were examined.Results: The urinary levels of podocalyxin were measured in 433 participants with a mean age of 25.3 years.Of these participants, 233 (54%) were female, and 333 (77%) were indigenous.A history of small for gestational age (SGA) was identified in 64 (15 %) participants.The median urinary podocalyxin level was 2.5 (IQR 1.2-4.7)g/g, showing a right-skewed distribution.Higher urinary podocalyxin excretion was associated with female sex, non-indigenous, higher birth weight, absence of SGA history, lower BMI, less current smoking, and greater albuminuria.In contrast, blood pressure, eGFR, and diabetes status were not significantly associated with urinary podocalyxin.Multivariable linear regression analysis revealed that non-indigenous and higher urinary albumin excretion remained independently associated with higher urinary podocalyxin excretion after adjusting for sex, SGA history, and smoking status.Conclusion: This is the first community-based study to evaluate urinary podocyte markers in young adults without apparent CKD.Our results suggest that subclinical podocyte injury, as indicated by albuminuria within the normal range, and genetic or racial factors, such as nephron number or total podocyte number per kidney, are both associated with urinary podocalyxin excretion.Further longitudinal studies are needed to determine the significance of urinary podocyte markers in predicting the incidence of CKD.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Kabasawa et al. (Wed,) studied this question.